All In MedTech

Device Trial Radar · NCT01934218

Gel-One Treatment in Knee Osteoarthritis

A Multi-Center, Randomized, Double-Blind, Phosphate Buffered Saline-Controlled Study to Evaluate Effectiveness and Safety of a Single Intra-Articular Injection of Gel-One® for the Treatment of Osteoarthritis of the Knee With Open-Label Safety Extension

Last checked: Nov 20, 2026Latest source record: Mar 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 814 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

814

Actual

Start

Aug 2013

Primary completion

Mar 2016

Study completion Mar 2016

Sponsor

Lead sponsor
Seikagaku CorporationNot on our public-company list
Sponsor type
Industry
Collaborators
Zimmer Biomet
First posted
Sep 4, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether Gel-One demonstrates a superior effectiveness in osteoarthritis (OA) knee pain compared with phosphate buffered saline (PBS) injections.

Conditions

  • Osteoarthritis Knee

Interventions

  • Gel-OneDevice

  • PBSDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Visual Analogue Scores (VAS) Following 50-foot Walk Test Through Week 26Time frame: Baseline up to Week26

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

40 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.